One poster demonstrating cell-free DNA molecular response as a potential surrogate endpoint to measure clinical efficacy of azenosertib in ...

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class i targeted and immune-mediated therapeutics to fight cancer, today announced that an ...

Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide ...

The abstracts will be available on the AACR 2025 meeting website. The posters will be available online at Erasca.com/science/presentations following the presentations.

The company's novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients ... anticipated therapeutic benefit and regulatory ...

The posters can be accessed through the “Supporting ... as a monotherapy and combination clinical studies in ovarian cancer and additional tumor types. WEE1 acts as a master regulator of the ...

The company’s novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients ... therapeutic benefit and regulatory development ...

Update on IND-enabling data for MP0712, a Radio-DARPin targeting DLL3 and labeled with 212Pb, co-developed with Orano Med; entering FIH studies in 2025 for the treatment of small cell lung cancer Firs ...

today announced a poster regarding the Company's clinical asset, CT-95, a mesothelin ("MSLN”) x CD3 TCE will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025, ...

The posters can be accessed through the “Supporting Publications ... currently being evaluated as a monotherapy and combination clinical studies in ovarian cancer and additional tumor types. WEE1 acts ...